Monitor the company's cash runway and clinical trial milestones. The filing provides maximum flexibility to raise capital, and actual dilution will depend on the pace and price of ATM sales. The next catalyst is likely data from the Phase 3 REGEN-006 (PROACT1) study.
Price Chart
Executive Summary
ProKidney Corp. filed a universal shelf registration statement on Form S-3 to register up to $650 million in securities, including a $200 million at-the-market (ATM) equity facility with Jefferies. The company has no approved products and no revenue, and its most recent 10-Q (June 30, 2026) showed a net tangible book value of $222.8 million. The filing signals potential significant dilution, as the ATM alone could increase the share count by up to 63% at the current price of $1.52 per share.
Key Financial Metrics
Key Facts
- ProKidney filed a universal shelf S-3 registering up to $650 million in securities.
- The filing includes an ATM facility with Jefferies for up to $200 million of Class A common stock.
- As of June 30, 2026, the company had a net tangible book value of $222.8 million ($0.74 per share on a combined Class A and Class B basis).
- The company has no approved products and has not generated any revenue from product sales.
- At the October 28, 2026 closing price of $1.52 per share, selling the full $200 million ATM would require issuing approximately 131.6 million shares, representing about 63% dilution relative to the 208.9 million Class A shares outstanding as of August 10, 2026.
- The company's market cap is $458 million, making the potential ATM size equal to approximately 44% of market cap.
- The company's cash burn and need for capital are evident from its pre-revenue, late-clinical-stage status.
Financial Impact
Potential dilution of up to 63% from the $200 million ATM alone, with total shelf capacity of $650 million representing 142% of current market cap.
Risk Factors
- Significant dilution risk from potential ATM sales and other offerings under the shelf.
- Pre-revenue biotech with no approved products and ongoing cash burn.
- Stock price could be pressured by the overhang of a large registered offering.
- Short interest of 8.1% indicates existing bearish sentiment.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 2 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3 Filing (Primary) | 0001193125-26-437924 |
| Document: d81716dex44.htm | 0001193125-26-437924 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 29, 2026 2d ago | 8-K | $1.51 | awaiting T+20 | awaiting T+20 | $1.29 (+14.24%) |
Oct 29, 2026 3d ago | S-3 | $1.51 | awaiting T+20 | awaiting T+20 | $1.29 (+14.24%) |
Oct 22, 2026 10d ago | Press Release | $1.43 | awaiting T+20 | awaiting T+20 | $1.29 (−9.44%) |
Aug 10, 2026 11w ago | 8-K | No price | awaiting T+20 | awaiting T+20 | No price |
Aug 10, 2026 11w ago | Press Release | $1.61 $1.85 | ▲ +14.91% | ▲ +15.97% | $1.29 (−19.57%) |
May 15, 2026 24w ago | 8-K | No price | awaiting T+20 | awaiting T+20 | No price |
May 15, 2026 24w ago | Press Release | $1.66 $1.67 | ▲ +0.60% | ▼ −1.52% | $1.29 (−21.99%) |
Apr 17, 2026 28w ago | DEFA14A | $2.10 $1.61 | ▼ −23.33% | ▼ −27.54% | $1.29 (−38.33%) |
Mar 18, 2026 32w ago | Press Release | $1.95 $2.18 | ▲ +11.79% | ▲ +4.17% | $1.29 (−33.59%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers